Manufacturers With High Concentrations of Lidocaine Receive FDA Warnings

Overview

The FDA issued warning letters to six companies for marketing unapproved topical analgesics with lidocaine concentrations exceeding 4%.

Background

The regulation of topical analgesics is crucial to ensure consumer safety, particularly as these products are often used in cosmetic procedures. High concentrations of lidocaine can lead to significant adverse effects.

Data Highlights

No numerical data provided in the source material.

Key Findings

• The FDA warned six companies for marketing topical analgesics with lidocaine concentrations exceeding 4%.
• High concentrations of lidocaine can lead to serious adverse effects, including arrhythmias, seizures, and respiratory difficulties.
• Consumers are advised to avoid topical analgesics with more than 4% lidocaine and to apply them only to small areas of skin.
• The FDA requested that healthcare providers report adverse events related to these products to its MedWatch program.
• These products are considered illegal.

Clinical Implications

Healthcare providers should be aware of the risks associated with high-concentration lidocaine products.

Conclusion

The FDA's actions highlight the need for regulatory compliance in the marketing of topical analgesics.

Related Resources & Content

1. FDA, FDA, 2024 -- FDA Warns Consumers to Avoid Certain Topical Pain Relief Products Due to Potential for Dangerous Health Effects
2. U.S. Food and Drug Administration Final Administrative Order, FDA, 2023 -- Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use
3. conexiant — FDA Warns Physicians of Tianeptine Dangers
4. Associated Press Health — FDA issues warning to 18 websites selling unapproved Botox
5. Pediatric Anesthesia — Plasma Lidocaine Concentrations During Intravenous Lidocaine Infusion Therapy in the Pediatric Population—A Scoping Review
6. reuters — US FDA Rejects Opioid Overdose Treatment Approval
7. FDA Warns Consumers to Avoid Certain Topical Pain Relief Products Due to Potential for Dangerous Health Effects | FDA
8. U.S. Food and Drug Administration Final Administrative Order (OTC000033): Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use
9. TKTX Numb Store - 697051 - 02/25/2025 | FDA
10. The state of local anaesthetic systemic toxicity in 2025: the emergence of lidocaine as our next challenge - PMC
11. Seizure following in-office lidocaine administration: a case report on local anesthetic systemic toxicity - PubMed
12. Local Anesthetic Systemic Toxicity Caused by Non-Anesthesiologists: A Narrative Review of Case Reports - PMC
13. ASRA Practice Advisory on Local Anesthetic Systemic Toxicity | Regional Anesthesia & Pain Medicine
14. Checklist for Treatment of Local Anesthetic Systemic Toxicity (LAST)
15. Office-based surgery clinical guidelines
16. Risk-Stratified Use of Topical and Infiltrative Local Anesthetics in High-Risk Dermatologic Surgery - PMC